All In Biotech

Drug Trial Radar · NCT07529717

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

May 18, 2026

Primary completion

Nov 17, 2027

Study completion Nov 17, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).

Conditions

  • Metastatic Prostate Cancer

Interventions

  • AZD8359Drug

    AZD8359 Monotherapy Administration route 1

  • AZD8359Drug

    AZD8359 Monotherapy Administration route 2

  • AZD8359Drug

    AZD8359 Monotherapy Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 1 (RDE1)

  • AZD8359Drug

    AZD8359 Monotherapy Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 2 (RDE2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)Time frame: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)
  2. Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)Time frame: From first study dose to 21 OR 28 days post first dose based on schedule
  3. PSA response rate (Part B only)Time frame: Up to 3 years

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Orlando, Florida · Active not recruiting

  • Research Site

    East Brunswick, New Jersey · Recruiting

  • Research Site

    Hackensack, New Jersey · Withdrawn

  • Research Site

    Providence, Rhode Island · Completed

  • Research Site

    Darlinghurst, Australia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.